Published in Photochem Photobiol on September 01, 1998
Photodynamic dose does not correlate with long-term tumor response to mTHPC-PDT performed at several drug-light intervals. Med Phys (2008) 1.02
Intraperitoneal photodynamic therapy mediated by a fullerene in a mouse model of abdominal dissemination of colon adenocarcinoma. Nanomedicine (2011) 0.91
PDT dose parameters impact tumoricidal durability and cell death pathways in a 3D ovarian cancer model. Photochem Photobiol (2013) 0.86
Impact of treatment response metrics on photodynamic therapy planning and outcomes in a three-dimensional model of ovarian cancer. J Biomed Opt (2013) 0.81
Minimally-invasive debulking of ovarian cancer in the rat pelvis by means of photodynamic therapy using the pegylated photosensitizer PEG-m-THPC. Br J Cancer (1999) 0.75
Time resolved reflectance and transmittance for the non-invasive measurement of tissue optical properties. Appl Opt (1989) 4.42
Optical properties of Intralipid: a phantom medium for light propagation studies. Lasers Surg Med (1992) 3.34
In vivo fluorescence spectroscopy and imaging for oncological applications. Photochem Photobiol (1998) 3.18
Volume CT with a flat-panel detector on a mobile, isocentric C-arm: pre-clinical investigation in guidance of minimally invasive surgery. Med Phys (2005) 3.17
Monte Carlo modeling of light propagation in highly scattering tissue--I: Model predictions and comparison with diffusion theory. IEEE Trans Biomed Eng (1989) 2.08
Spatially resolved absolute diffuse reflectance measurements for noninvasive determination of the optical scattering and absorption coefficients of biological tissue. Appl Opt (1996) 2.05
A Monte Carlo model for the absorption and flux distributions of light in tissue. Med Phys (1984) 1.87
Image guided photothermal focal therapy for localized prostate cancer: phase I trial. J Urol (2009) 1.84
Three-dimensional miniature endoscopy. Nature (2006) 1.82
Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol (2001) 1.82
Targeted antimicrobial photochemotherapy. Antimicrob Agents Chemother (1998) 1.79
Quantitative, single-tube, kinetic-dependent enzyme-linked immunosorbent assay (k-ELISA). Methods Enzymol (1983) 1.72
Combination photoimmunotherapy and cisplatin: effects on human ovarian cancer ex vivo. J Natl Cancer Inst (1999) 1.71
In vivo high-resolution fluorescence microendoscopy for ovarian cancer detection and treatment monitoring. Br J Cancer (2009) 1.51
Autofluorescence endoscopy: feasibility of detection of GI neoplasms unapparent to white light endoscopy with an evolving technology. Gastrointest Endosc (2001) 1.48
The use of India ink as an optical absorber in tissue-simulating phantoms. Phys Med Biol (1992) 1.44
A mechanistic study of cellular photodestruction with 5-aminolaevulinic acid-induced porphyrin. Br J Cancer (1994) 1.43
Photophysical and photosensitizing properties of benzoporphyrin derivative monoacid ring A (BPD-MA). Photochem Photobiol (1994) 1.42
Antibody-targeted photolysis: selective photodestruction of human T-cell leukemia cells using monoclonal antibody-chlorin e6 conjugates. Proc Natl Acad Sci U S A (1986) 1.36
Changes in in vivo optical properties and light distributions in normal canine prostate during photodynamic therapy. Radiat Res (1997) 1.35
Kinetic studies of a quantitative single-tube enzyme-linked immunosorbent assay. Clin Chem (1980) 1.33
Singlet oxygen luminescence as an in vivo photodynamic therapy dose metric: validation in normal mouse skin with topical amino-levulinic acid. Br J Cancer (2005) 1.32
Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology (1994) 1.27
Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys. Ophthalmology (1996) 1.25
Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol (1995) 1.24
Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci Lett (2002) 1.23
Photodynamic synovectomy using benzoporphyrin derivative in an antigen-induced arthritis model for rheumatoid arthritis. Photochem Photobiol (1998) 1.21
Experimental photoimmunotherapy of hepatic metastases of colorectal cancer with a 17.1A chlorin(e6) immunoconjugate. Cancer Res (2000) 1.20
Epidermal growth factor receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer in vivo. Cancer Res (2001) 1.18
Schistosoma mansoni adult microsomal antigens, a serologic reagent. I. Systematic fractionation, quantitation, and characterization of antigenic components. J Immunol (1983) 1.17
Effect of charge on the interaction of site-specific photoimmunoconjugates with human ovarian cancer cells. Cancer Res (1996) 1.17
Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells. Br J Cancer (2006) 1.16
In vivo near-infrared Raman spectroscopy: demonstration of feasibility during clinical gastrointestinal endoscopy. Photochem Photobiol (2000) 1.16
Pegylation of a chlorin(e6) polymer conjugate increases tumor targeting of photosensitizer. Cancer Res (2001) 1.15
Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. J Pharmacol Exp Ther (2000) 1.14
Photodynamic treatment of rheumatoid and inflammatory arthritis. Photochem Photobiol (1996) 1.13
A solubilization technique for photosensitizer quantification in ex vivo tissue samples. J Photochem Photobiol B (1997) 1.13
In vivo tests of the concept of photodynamic threshold dose in normal rat liver photosensitized by aluminum chlorosulphonated phthalocyanine. Photochem Photobiol (1990) 1.12
Comparison of narrowband ultraviolet B exposure and oral vitamin D substitution on serum 25-hydroxyvitamin D concentration. Br J Dermatol (2012) 1.12
Photoimmunotherapy of human ovarian carcinoma cells ex vivo. Cancer Res (1991) 1.12
Differentiation-specific increase in ALA-induced protoporphyrin IX accumulation in primary mouse keratinocytes. Br J Cancer (1998) 1.12
Monte Carlo modeling of light propagation in highly scattering tissues--II: Comparison with measurements in phantoms. IEEE Trans Biomed Eng (1989) 1.12
In vivo quantification of fluorescent molecular markers in real-time by ratio imaging for diagnostic screening and image-guided surgery. Lasers Surg Med (2007) 1.11
Optical and thermal characterization of natural (Sepia officinalis) melanin. Photochem Photobiol (1994) 1.11
Effects of femtosecond laser irradiation on osseous tissues. Lasers Surg Med (2007) 1.11
Photodynamic therapy of orthotopic prostate cancer with benzoporphyrin derivative: local control and distant metastasis. Cancer Res (1998) 1.11
Localization of lipoprotein-delivered benzoporphyrin derivative in the rabbit eye. Curr Eye Res (1997) 1.10
Experimental tests of the feasibility of singlet oxygen luminescence monitoring in vivo during photodynamic therapy. J Photochem Photobiol B (1990) 1.09
Targeted photodestruction of human colon cancer cells using charged 17.1A chlorin e6 immunoconjugates. Br J Cancer (2000) 1.08
The physics of photodynamic therapy. Phys Med Biol (1986) 1.08
Reduction by naloxone of lipopolysaccharide-induced neurotoxicity in mouse cortical neuron-glia co-cultures. Neuroscience (2000) 1.07
Photoluminescence spectroscopy of carbon nanotube bundles: evidence for exciton energy transfer. Phys Rev Lett (2007) 1.07
BPD-MA-mediated photosensitization in vitro and in vivo: cellular adhesion and beta1 integrin expression in ovarian cancer cells. Br J Cancer (1999) 1.07
Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library. J Immunol Methods (2001) 1.06
Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model. Cancer Res (1996) 1.06
Narrowband ultraviolet B treatment improves vitamin D balance and alters antimicrobial peptide expression in skin lesions of psoriasis and atopic dermatitis. Br J Dermatol (2010) 1.06
The effect of charge on cellular uptake and phototoxicity of polylysine chlorin(e6) conjugates. Photochem Photobiol (1997) 1.06
The effects of the HIV-1 envelope protein gp120 on the production of nitric oxide and proinflammatory cytokines in mixed glial cell cultures. Cell Immunol (1996) 1.06
Photodynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin. Ophthalmology (1994) 1.06
Characterization of a xenograft model of human ovarian carcinoma which produces intraperitoneal carcinomatosis and metastases in mice. Int J Cancer (1996) 1.05
Tumor-secreted vascular permeability factor/vascular endothelial growth factor influences photosensitizer uptake. Cancer Res (1993) 1.04
Ultrasound properties of liver tissue during heating. Ultrasound Med Biol (1997) 1.04
Benzophenothiazine and benzoporphyrin derivative combination phototherapy effectively eradicates large murine sarcomas. Photochem Photobiol (1996) 1.03
Biodistribution and phototoxicity of 5-aminolevulinic acid-induced PpIX in an orthotopic rat bladder tumor model. J Urol (1995) 1.03
Erythroderma: a follow-up of fifty cases. J Am Acad Dermatol (1983) 1.02
In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization. Lasers Surg Med (1995) 1.01
The effects of aggregation, protein binding and cellular incorporation on the photophysical properties of benzoporphyrin derivative monoacid ring A (BPDMA). J Photochem Photobiol B (1995) 1.00
Integrin-mediated adhesion and signalling in ovarian cancer cells. Cell Signal (1998) 1.00
Photoimmunotherapy and biodistribution with an OC125-chlorin immunoconjugate in an in vivo murine ovarian cancer model. Br J Cancer (1994) 1.00
Differentiation enhances aminolevulinic acid-dependent photodynamic treatment of LNCaP prostate cancer cells. Br J Cancer (2002) 0.99
Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season. Clin Exp Immunol (2007) 0.99
Biodistribution of charged F(ab')2 photoimmunoconjugates in a xenograft model of ovarian cancer. Br J Cancer (1997) 0.99
Why do veins appear blue? A new look at an old question. Appl Opt (1996) 0.99
In vivo and post mortem measurements of the attenuation spectra of light in mammalian tissues. Photochem Photobiol (1985) 0.98
Advantages of a dual-tracer model over reference tissue models for binding potential measurement in tumors. Phys Med Biol (2012) 0.98
Phototoxicity of lumidoxycycline. J Invest Dermatol (1993) 0.98
Determination of optical properties of turbid media using pulsed photothermal radiometry. Phys Med Biol (1992) 0.98
Investigations of large vessel cooling during interstitial laser heating. Med Phys (1995) 0.98
Photodynamic therapy for recurrent supratentorial gliomas. Semin Surg Oncol (1995) 0.97
Photodynamic therapy of intracranial tissues: a preclinical comparative study of four different photosensitizers. J Clin Laser Med Surg (1998) 0.97
In vivo fluence rate and fractionation effects on tumor response and photobleaching: photodynamic therapy with two photosensitizers in an orthotopic rat tumor model. Cancer Res (1999) 0.97
Apoptosis induced in vivo by photodynamic therapy in normal brain and intracranial tumour tissue. Br J Cancer (2000) 0.96
Mechanisms of resistance to photodynamic therapy. Curr Med Chem (2011) 0.96
The measurement of dihematoporphyrin ether concentration in tissue by reflectance spectrophotometry. Photochem Photobiol (1987) 0.96
Schistosoma mansoni adult microsomal antigens, a serologic reagent. II. Specificity of antibody responses to the S. mansoni microsomal antigen (MAMA). J Immunol (1983) 0.96
The use of a neural network to determine tissue optical properties from spatially resolved diffuse reflectance measurements. Phys Med Biol (1992) 0.96
Pegylation of charged polymer-photosensitiser conjugates: effects on photodynamic efficacy. Br J Cancer (2003) 0.96
Frequency-domain reflectance for the determination of the scattering and absorption properties of tissue. Appl Opt (1991) 0.95
Photodynamic therapy of malignant primary brain tumours: clinical effects, post-operative ICP, and light penetration of the brain. Photochem Photobiol (1987) 0.95
Androgens induce oxidative stress and radiation resistance in prostate cancer cells though NADPH oxidase. Prostate Cancer Prostatic Dis (2009) 0.95
Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. J Clin Oncol (2001) 0.95
Autonomic dysreflexia in a paraplegic man with catecholamine-secreting neuroblastoma. Arch Phys Med Rehabil (1986) 0.94
Rhodamine dyes as potential agents for photochemotherapy of cancer in human bladder carcinoma cells. Cancer Res (1989) 0.94
A multicenter study of patch test reactions with dental screening series. Am J Contact Dermat (2001) 0.94
Photodynamic targeting of human retinoblastoma cells using covalent low-density lipoprotein conjugates. Br J Cancer (1997) 0.94
Absorption spectroscopy in tissue-simulating materials: a theoretical and experimental study of photon paths. Appl Opt (1995) 0.94
Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model. Br J Cancer (1996) 0.94
Clinical and laboratory characteristics of Finnish lupus erythematosus patients with cutaneous manifestations. Lupus (2008) 0.93